Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23579228 | 1.00 | HPGD (0.44) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL14671914 | 0.88 | HPGD (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL15105073 | 0.88 | HPGD (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL14671917 | 0.88 | HPGD (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL17517752 | 0.85 | NR1H2 (0.41) | HPGDRECQLUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL23578918 | 0.84 | HPGD (0.43) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL23817330 | 0.82 | HPGD (0.44) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL23578969 | 0.82 | HPGD (0.44) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL21111211 | 0.82 | HPGD (0.44) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL16653187 | 0.82 | HPGD (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| CN-115135642-B | Inhibitors of EGFR mutant forms | 缆图药品公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12172983-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230056541-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-02-23 | — | — | US | disclosed |
| US-20230026209-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-01-26 | — | — | US | disclosed |
| EP-4081515-A1 | INHIBITORS OF MUTANT FORMS OF EGFR | Blueprint Medicines Corporation (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115135642-A | Inhibitors of mutant forms of EGFR | 缆图药品公司 | 2022-09-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056541-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | HPGD 3657/4885RECQL 4012/4885EPHX1 3888/4885 |
| US-20230026209-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | HPGD 3657/4885RECQL 4012/4885EPHX1 3888/4885 |
| US-11718602-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | HPGD 3657/4885RECQL 4012/4885EPHX1 3888/4885 |
| US-12172983-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | HPGD 3657/4885RECQL 4012/4885EPHX1 3888/4885 |
| US-20250289801-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | HPGD 3657/4885RECQL 4012/4885EPHX1 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.